Azacitidine in Treating Patients With Myelofibrosis
Stopped early · Phase 2
Conditions studied: Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
In brief
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well azacitidine works in treating patients with myelofibrosis.
Key facts
- Study ID
- NCT00381693
- Run by
- Mayo Clinic
- People needed
- 10
- Starts
- 2006-08-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2011-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.